Dare Bioscience, Inc.
DARE
Positions held
Your positionsDARE isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $15.19M | Enterprise value | $5.95M | Trailing P/E | — | Forward P/E | -1.86 |
| PEG | — | Price / book | -20.87 | Beta | 1.01 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 2.4% | Operating margin | -15.8% |
| Profit margin | 0.0% | ROE | — | ROA | -39.3% | Debt / equity | — |
| Current ratio | 0.99 | Free cash flow | -$6.91M | Analyst recommendation | none | Mean target | $8.33 |
| 52w high | $3.78 | 52w low | $0.69 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | $0.2M | $1.0M | $0.0M | -$0.0M | — |
| Op margin | -1582.5% | -1967.1% | -143.7% | -162340.8% | 18079.5% | — |
| Net income | -$3.0M | -$3.0M | -$1.4M | -$3.6M | -$4.0M | — |
| Gross margin | -70.6% | -58.9% | 71.1% | 100.0% | 100.0% | — |
| Gross profit | -$0.1M | -$0.1M | $0.7M | $0.0M | -$0.0M | — |
| Operating income | -$3.0M | -$3.0M | -$1.5M | -$3.7M | -$3.8M | — |
- Revenue +23% vs prior quarter ($0.2M vs $0.2M).
- Gross margin -70.6% (was -59% prior quarter).
- Operating margin expanded to -1582.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.0M | $0.0M | $2.8M | $10.0M | — |
| Op margin | -1315.5% | -239692.2% | -1101.9% | -313.9% | — |
| Net income | -$13.4M | -$4.1M | -$30.2M | -$30.9M | — |
| Gross margin | 71.3% | — | — | — | — |
| Gross profit | $0.7M | — | — | — | — |
| Operating income | -$13.6M | -$23.5M | -$30.9M | -$31.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · Dare Bioscience stock rises after receiving HPV treatment patent
2026-09-11 · Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
2026-08-27 · Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
2026-08-20 · Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript
2026-08-18 · DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
2026-08-17 · Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ...
Price (daily)
Full chart · RSI · MACD · patterns